These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 29599766)
1. Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity. Wagner-Muñiz DA; Haughney SL; Kelly SM; Wannemuehler MJ; Narasimhan B Front Immunol; 2018; 9():325. PubMed ID: 29599766 [No Abstract] [Full Text] [Related]
2. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection. Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953 [TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869 [TBL] [Abstract][Full Text] [Related]
4. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Bosarge JR; Watt JM; McDaniel DO; Swiatlo E; McDaniel LS Infect Immun; 2001 Sep; 69(9):5456-63. PubMed ID: 11500417 [TBL] [Abstract][Full Text] [Related]
5. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments. Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747 [TBL] [Abstract][Full Text] [Related]
6. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Genschmer KR; Accavitti-Loper MA; Briles DE Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169 [TBL] [Abstract][Full Text] [Related]
7. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325 [TBL] [Abstract][Full Text] [Related]
8. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Xin W; Li Y; Mo H; Roland KL; Curtiss R Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204 [TBL] [Abstract][Full Text] [Related]
9. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500 [TBL] [Abstract][Full Text] [Related]
10. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027 [TBL] [Abstract][Full Text] [Related]
11. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections. Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490 [TBL] [Abstract][Full Text] [Related]
12. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains. Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745 [TBL] [Abstract][Full Text] [Related]
13. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740 [TBL] [Abstract][Full Text] [Related]
14. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice. Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043 [TBL] [Abstract][Full Text] [Related]
15. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies. da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805 [TBL] [Abstract][Full Text] [Related]
16. Immunization with PspA incorporated into a poly(ethylene oxide) matrix elicits protective immunity against Streptococcus pneumoniae. Moore QC; Johnson L; Repka M; McDaniel LS Clin Vaccine Immunol; 2007 Jun; 14(6):789-91. PubMed ID: 17460113 [TBL] [Abstract][Full Text] [Related]
17. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice. Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026 [TBL] [Abstract][Full Text] [Related]
18. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Moore QC; Bosarge JR; Quin LR; McDaniel LS Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765 [TBL] [Abstract][Full Text] [Related]
19. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319 [TBL] [Abstract][Full Text] [Related]
20. Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy. Dorosti H; Eslami M; Nezafat N; Fadaei F; Ghasemi Y Mol Cell Probes; 2019 Dec; 48():101446. PubMed ID: 31520715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]